Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: TimeToMakeTheInvs who wrote (7319)	3/29/1999 1:27:00 PM
From: Ibexx	Read Replies (1) \| Respond to of 9523

Time to Make, My opinion regarding a rumored Glaxo/BMY merger was based upon years of professional experience in the pharmaceutical industry. BMY is an extremely innovative company--its angiotensin inhibitors revolutionized hypertensive therapy, for example--whereas Glaxo is somewhat stodgy with uneven R&D and marketing performance. (No hate mail, please). If merged, BMY could get the short end of the stick and suffer from organizational suffocation. The cultural misfits between the two companies are quite obvious to those who are in the know. There are other product issues are well, but I will not elaborate here due to complexities involved. BTW, I don't worry about Pfizer's competitive position. In this business, competition is a way of life. Ibexx